Meeting
2022 ASCO Annual Meeting
Adherence to oral treatments in elderly patients with advanced prostate cancer: The ADHERE study, a prospective trial of the Meet-URO network.
Authors
Pasquale Rescigno
Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy
Pasquale Rescigno , Marco Maruzzo , Sara Elena Rebuzzi , Veronica Murianni , Marika Cinausero , Helga Lipari , Lucia Fratino , Teresa Gamba , Ugo De Giorgi , Orazio Caffo , Davide Bimbatti , Arianna Dri , Alessandra Mosca , Emilio Francesco Giunta , Paola Ermacora , Massimo Di Maio , Umberto Basso , Giuseppe Fornarini , Giuseppe Luigi L. Banna
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Symptoms and Survivorship
Track
Symptom Science and Palliative Care
Sub Track
Geriatric Models of Care
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 12044)
DOI
10.1200/JCO.2022.40.16_suppl.12044
Abstract #
12044
Poster Bd #
290
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Genitourinary Cancers Symposium
Survival in Black and non-Black patients with metastatic prostate cancer.
First Author: Nina Cheranda
Poster
2024 ASCO Genitourinary Cancers Symposium
Somatostatin receptor 1 (SSTR1) expression as a potential predictive biomarker for response to androgen receptor signaling inhibitor (ARSI) therapy in metastatic castration-resistant prostate cancer (mCRPC).
First Author: Xiaolin Zhu
Poster
2024 ASCO Genitourinary Cancers Symposium
Interaction of age and benefit of treatment intensification in advanced prostate cancer: An aggregate meta-analysis of 14 randomized trials.
First Author: Alicia K. Morgans
Poster
2024 ASCO Genitourinary Cancers Symposium
Real-world experience on tolerability and safety of relugolix combined with androgen signaling inhibitors in patients with advanced prostate cancer.
First Author: Jian Guan